Cardiovascular Disease

The ASPC launches a new working group to guide the safe, evidence-based integration of AI and digital health technologies into preventive cardiology practice - we spoke to co-Chair Dr Ashish Sarraju about the state of artificial intelligence and health technology and the group's concerns plans for the future.

The ASPC launches a new working group to advance women in preventive cardiology, tackling gaps in mentorship, leadership, and representation while improving cardiovascular care for women - we spoke to co-Chair Dr Kardie Tobb about the groups' inception and their plans for reducing inequality for women cardiologists.

The ASPC’s new Women’s Cardiovascular Health Working Group highlights sex-specific risk factors and prevention strategies, offering critical insights for improving outcomes in female patients - we spoke to co-Chair Dr Martha Gulati about the inception of the group and their goals for preventing cardiovascular disease in women.

New data to be presented at ACC 2026 suggest that shingles vaccination is associated with a reduced risk of major cardiovascular events, including myocardial infarction and stroke. In a large observational analysis, vaccinated individuals showed lower event rates within 12 months of follow-up. While the findings are subject to study limitations, they add to growing evidence linking infection prevention with cardiovascular risk reduction.

We often focus on clinical excellence, but spend less time developing broader skills that could help us better lead with purpose and build more fulfilling, impactful careers. In this episode, part of a mini-series in partnership with LEADderm, Dr Jennifer Soung and Denise Mann explore how clinicians can engage with the media to educate, empower and extend their impact beyond the clinic.

Europe loses 1.7 million lives each year to cardiovascular disease, a burden that costs billions and affects millions more. The Safe Hearts Plan sets out an ambitious shift toward prevention, earlier detection and recognition of lifelong genetic risk. As expectations rise, debate is already growing over whether the strategy can translate bold goals into measurable improvements in care and outcomes across the EU.

We are delighted to welcome Dr Sushant Saluja, NIHR Clinical Lecturer in Cardiology at the University of Manchester, to our Editorial Board. Dr Saluja brings a distinguished record in interventional cardiology, population genetics and precision medicine, with research published in leading journals including Nature Genetics, Nature Communications, European Heart Journal and the Journal of Hypertension.

This video highlights the efficacy and safety of lomitapide in paediatric patients with homozygous familial hypercholesterolaemia (HoFH) in the Phase III APH-19 trial.

The American Diabetes Association has released its 2026 Standards of Care, reflecting major advances in diabetes and cardiometabolic management. In this Q&A, Dr Robert Gabbay (Joslin Diabetes Center, Boston, MA, USA) discusses expanded roles for GLP-1–based therapies, updated cardiovascular risk targets, and a growing emphasis on integrated, whole-person care with important implications for cardiovascular clinical practice.